In AML models, BZM has been reported as a potent inhibitor of DNA methylation in malignant cells by interfering with Sp1/NF-κB DNA–binding activity, which in turn results in decreased DNMT1 expression, DNA hypomethylation, and transcription of methylation-silenced genes [6]. Here, NFKB1 is linked to acute myeloid leukemia.